Biomarin Pharmaceutical (BMRN) Gross Margin (2009 - 2026)
Biomarin Pharmaceutical (BMRN) posted Gross Margin of 74.55% for Q1 2026, up 8.87% on a QoQ basis from 68.47% in Q4 2025, and down 511.0% year-over-year from 18.14% in Q1 2025.
Biomarin Pharmaceutical (BMRN) Gross Margin (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical's Gross Margin history runs 18 years deep, the most recent figure standing at 74.55% for Q1 2026.
- Quarterly Gross Margin fell 511.0% year-over-year to 74.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.53% (down 291.0% YoY) and the FY2025 annual result came in at 77.73%, down 194.0% from the prior year.
- Gross Margin was 74.55% for Q1 2026 at Biomarin Pharmaceutical, up from 68.47% in the prior quarter.
- Across five years, Gross Margin topped out at 81.95% in Q3 2025 and bottomed at 68.47% in Q4 2025.
- A 5-year average of 77.73% and a median of 77.97% in 2023 frame the typical range for Gross Margin.
- Peak annual rise in Gross Margin reached 722 bps in 2025, while the deepest fall reached 1331 bps in 2025.
- Biomarin Pharmaceutical's Gross Margin stood at 72.72% in 2022, then advanced by 8 bps to 78.66% in 2023, then gained by 4 bps to 81.78% in 2024, then decreased by 16 bps to 68.47% in 2025, then rose by 9 bps to 74.55% in 2026.
- Business Quant data shows BMRN's Gross Margin at 74.55% in Q1 2026, 68.47% in Q4 2025, and 81.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 88.95% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 86.85% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 91.79% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 90.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.33 Bn | 9.11 Bn | 571.21 Mn | 74.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.55% |
| Dec 31, 2025 | 68.47% |
| Sep 30, 2025 | 81.95% |
| Jun 30, 2025 | 81.82% |
| Mar 31, 2025 | 79.66% |
| Dec 31, 2024 | 81.78% |
| Sep 30, 2024 | 74.73% |
| Jun 30, 2024 | 81.68% |
| Mar 31, 2024 | 80.71% |
| Dec 31, 2023 | 78.66% |
| Sep 30, 2023 | 77.97% |
| Jun 30, 2023 | 78.06% |
| Mar 31, 2023 | 77.29% |
| Dec 31, 2022 | 72.72% |
| Sep 30, 2022 | 76.99% |
| Jun 30, 2022 | 76.93% |
| Mar 31, 2022 | 77.48% |
| Dec 31, 2021 | 73.38% |
| Sep 30, 2021 | 74.67% |
| Jun 30, 2021 | 74.67% |